Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 532637 | NSE Symbol : MANGALAM | ISIN : INE584F01014 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
14-May-2025	17-May-2025	Quarterly Results	Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2025 inter alia to consider and approve Intimation of Board meeting to be held on 17th May 2025 inter-alia to approve Audited Financial Results(standalone and consolidated) for the quarter and year ended 31st March 2025. Outcome of Board meeting held on 17th May, 2025 at 5:00 p.m. to approve Audited Financial Results of the Company for the quarter and year ended 31st March 2025 (As Per BSE Announcement Dated on :17.05.2025)
04-Apr-2025	11-Apr-2025	Change in Other Executives	Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/04/2025 inter alia to consider and approve Intimation of Board Meeting to be held on 11th April 2025 for approval of appointment of Chief Financial Officer of the Company w.e.f. 11th April 2025. Outcome of Board meeting held on Friday, 11th April, 2025 at 2:00 P.M. inter alia, for approval of following Businesses: Appointment of Chief Financial Officer , Internal Auditor, Cost Auditor of the Company (As per BSE Announcement Dated on 11/04/2025)
29-Mar-2025	29-Mar-2025	Change in Other Executives	Outcome of Board meeting held on 29th March, 2025 for acceptance of the resignation tendered by Chief Financial Officer of the Company w.e.f. 31st March, 2025
05-Feb-2025	13-Feb-2025	Quarterly Results	MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Intimation of Board meeting to be held on 13th February 2025 for approval of Un-audited Financial results of the Company for the quarter ended 31st December 2024. Declaration of Un-Audited Financial Results for the quarter ended 31st December 2024 in the Board meeting held on 13th February 2025 (As Per BSE Announcement Dated on: 13/02/2025)
08-Nov-2024	14-Nov-2024	Quarterly Results	MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Pursuant to Regulation 29 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Un-Audited Financial Results of the Company for the Quarter ended 30th September 2024. Board meeting held on 14th November 2024 for declaration of Un-Audited Satandalone and Consolidated Financial Results for the quareter ended 30th September, 2024 (As per BSE Announcement dated on 14/11/2024)
06-Aug-2024	13-Aug-2024	Quarterly Results	MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Board Meeting to be held on 13th August 2024 intimation for approval of quarterly Financial Results of the Company for the quarter ended 30th June 2024 Approval of Un-audited Standalone and Consolidated Financial results for the quarter ended 30.06.2024 and re-appointment of Managing Director and Whole-time Director (As Per Bse Announcement Dated on 13.08.2024)
09-Jul-2024	08-Jul-2024	Change in Other Executives	Approval of appointment of Ms. Anuradha Pandey (ACS-72902) as a Company Secretary, Compliance Officer and Key Managerial Personnel of the Company w.e.f. 8th July, 2024 Board meeting dated 8th July , 2024 approved the appointment of Ms. Anuradha Pandey, (M.No. A72902) Company Secretary and Compliance Officer of the Company Board meeting held on 8th July, 2024 for approval of appointment of Ms. Anuradha Pandey (M. No. ACS-72902) Company Secretary and Compliance Officer and Key Managerial Personnel of the Company. (As Per BSE Announcement dated on 04.12.2024)
18-Jun-2024	18-Jun-2024	Scheme of Amalgamation	Board meeting outcome for consideration and approval of Scheme of arrangement by absorption.
14-May-2024	21-May-2024	Quarterly Results	Quarterly Results & Audited Results FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31 2024 AND OTHER AGENDA ITEMS Appointment of Internal Auditor for the FY 2024 25 (As Per BSE Announcement Dated on 21.05.2024)
08-Mar-2024	15-Mar-2024	Scheme of Amalgamation	MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/03/2024 inter alia to consider and approve The proposal of Scheme of Merger Intimation of Board meeting to be held on Friday 15th March 2024 Board of Directors at its meeting held on 15th March 2024 considered and approved the scheme of Merger by Absorption. The Board at its meeting held on 15.03.2024 Considered and approved the scheme of Merger by Absorption. (As Per BSE Announcement Dated on 16/03/2024)
06-Feb-2024	13-Feb-2024	Quarterly Results	MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results of the company for the period ended 31st December 2023 Submission of Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December 2023 (As Per BSE Announcement dated on 13.02.2024)
31-Oct-2023	08-Nov-2023	Quarterly Results	MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve Un audited financial results for the quarter ended 30.09.2023 MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 ,inter alia, to consider and approve Update on board meeting : To consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report there on for the quarter and half year ended September 30, 2023(Q2). (As Per BSE Announcement Dated on 01.11.2023) Standalone and consolidated financial results for the period ended 30.09.2023 Financial results for the period ended 30.09.2023 (As per BSE Announcement Dated on 08/11/2023)
01-Oct-2023	30-Sep-2023	Subsidiary Company	The Board of Directors in its meeting held on Saturday, September 30, 2023 has noted approval of transfer of 100 % shares in favor of the Company by Board of Directors of Mangalam Laboratories Private Limited in its Board Meeting held on September 30, 2023. Consequently, the Company has acquired 100 % stake in Mangalam Laboratories Private Limited thereby making it Wholly Owned Subsidiary of the Company.
03-Aug-2023	10-Aug-2023	Quarterly Results	MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve the Un-Audited Financial Results of the Company for the quarter ended June 30 2023(Q1). Pursuant to Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations) we wish to inform that the Board of Directors of the Company at its meeting held today i.e., August 10, 2023 inter-alia transacted the following business: 1. Considered & approved the Un-Audited Financial Results for the quarter ended June 30, 2023 along with the Limited Review Report on the results pursuant to Regulation 33 of the Listing Regulations (As per BSE Announcement Dated on 10/08/2023)
23-May-2023	30-May-2023	Accounts	MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve The Audited Financial Results of the Company for the quarter and year ended March 31 2023 (the Financial Results); Dear Sir / Madam, With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Tuesday, May 30, 2023 has inter-alia transacted the following business: The Audited Financial Results (Standalone) for the quarter and Financial Year ended March 31, 2023 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Auditor's Report is annexed hereto and marked as Annexure I.) Appointment of Internal Auditor of the Company for the Financial Year 2023-24. (Brief profile is attached herewith as Annexure II) Appointment Secretarial Auditor of the Company for Financial Year 2022-23. (Brief Profile is attached herewith as Annexure - III) Appointment of Internal Auditor of the Company for the Financial Year 2023-24. (Brief profile is attached herewith as Annexure II) (As Per BSE Announcement dated on 30.05.2023) With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held on Tuesday, May 30, 2023 has inter-alia transacted the following business: Appointment Secretarial Auditor of the Company for Financial Year 2022-23. (Brief Profile is attached herewith as Annexure - I) We request you to take the same on your records. (As Per BSE Announcement dated on 31.05.2023)

1 2 3

LOGIN HERE

Mangalam Drugs and Organics Ltd

Board Meeting